

under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

Please substitute the pending paragraph [0405] with the following paragraph [0405] at page 164:

17.2 Establishing Ig α and Ig β -expressing HeLaS3 and COS7 stable transfectants.

HeLaS3 and COS7 cells (1×10^6 per well in a 6-well plate) were transfected with 0.5 to 1 μ g each of the purified pIRESneo-Ig α and pIREShyg-Ig β plasmid DNA using the LIPOFECTAMINE PLUS Reagent (Life technologies). Starting two days later, cells were selected with G418 (at 0.4 mg/ml) and hygromycin B (at 0.2 mg/ml) for about 2 weeks. Drug-resistant HeLaS3 colonies were directly isolated and COS7 transfectants were cloned by limiting dilution. The expression of Ig α and Ig β in each of these clones was then analyzed by RT-PCR, and the results from the representative clones were as shown in Figure 14. A representative HeLaS3 transfectant, HeLaS3-Ig $\alpha\beta$, was deposited at the American Type Culture Collection (ATCC) Patent Depository, 10801 University Boulevard, Manassas, Virginia 20110-2209, as ATCC Deposit Number PTA-4006 on January 24, 2002.